Match Document Document Title
6485746 Controlled-release sedative-hypnotic compositions and methods related thereto  
Controlled-release formulations providing a “pulsed” plasma profile of a sedative-hypnotic compound having a particularly short half-life are provided. The formulation contains a sedative-hypnotic...
6482987 Pharmaceutical composition containing bupropion hydrochloride and a stabilizer  
Novel, stable formulations of bupropion hydrochloride are provided which will maintain at least 80% of initial bupropion hydrochloride potency after one year. Methods of inhibiting degradation of...
6482434 Method for reducing adverse effects of a weight loss regimen  
A method for reducing certain effects associated with a negative calorie balance in a human includes the step of administering conjugated linoleic acid to a human in an amount effective to reduce...
6475521 Biphasic controlled release delivery system for high solubility pharmaceuticals and method  
A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has...
6475779 Polymeric gene delivery  
A means for obtaining efficient introduction of exogenous genes into a patient, with long term expression of the gene, is disclosed. The gene, under control of an appropriate promoter for...
6468560 Controlled release dosage form of &lsqb R-(Z)&rsqb -α-(methoxyimino)-α-(1-azabicyclo&lsqb 2.2.2&rsqb oct-3yl) acetonitrile monohydrochloride  
A controlled release formulation of an acetonitrile compound and its use in the treatment and/or prophylaxis of certain disorders.
6468959 Peroral dosage form for peptide containing medicaments, in particular insulin  
There is provided a plural dosage form for peptide pharmaceuticals comprising a matrix of gelatin or gelatin derivative having distributed therein the peptide pharmaceutical in particular insulin,...
6461641 Tumor delivery vehicles  
The major problem with current direct delivery techniques of therapeutic reagents into solid tumors, especially of cells or large volumes of recombinant DNA reagents or drugs, has been resistance...
6458384 Pharmaceutical with predetermined activity profile  
A first pharmacologically active substance contained in a pharmaceutical, which acts on a specific biological function, is released according to a predetermined release profile (D.1), FIG. 1, and...
6451345 Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration  
The present invention provides taste-masked microcapsules of Linezolid or the like (any member of the orally effective oxazolidinone or macrolide antibiotics), suitable for oral administration as...
6451343 Composition for treating dementia and Alzheimer's disease  
Controlled release dosage forms useful in the treatment and/or prophylaxis of dementia, including Alzheimer's disease, in mammals, and for enhancing amyloid precursor protein processing along a...
6451341 Time release formulation of vitamins, minerals and other beneficial supplements  
The present invention concerns a formulation of vitamins, minerals and other beneficial supplements which has been demonstrated to be cancer-protective. It is believed that the formulations of the...
6451342 Core formulation comprised of troglitazone and a biguanide  
This invention relates to a controlled release combination drug product comprising troglitazone, e.g. its hydrochloride, and a biguamide, e.g. metformin. In particular, the product comprises a...
6451848 Compositions and methods comprising morphine gluconate  
The present invention relates to a pharmaceutical composition which includes morphine gluconate or chemical equivalent thereof. In one embodiment, the present invention includes a method of making...
6447797 Antibacterial phosphoinositides  
It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto...
6447807 Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery  
A method for making the potassium and sodium salts of (−)-hydroxycitric acid and mixtures thereof workable, non-hygroscopic and non-reactive in acidic media by encasement in hydrophobic and...
6444221 Methods of treating chronic inflammatory diseases using carbonyl trapping agents  
These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of...
6440457 Method of administering antidepressant dosage form  
The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.
6440459 Paroxetine maleate polymorph and pharmaceutical compositions containing it  
The form B of paroxetine maleate polymorph is characterized by determined data of X ray diffraction: it has a chemical stability which is superior to that of the form A of paroxetine maleate. This...
6440458 Sustained release preparations  
Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in...
6436438 Tramadol multiple unit formulations  
A multiple unit oral pharmaceutical dosage form having a plurality of pellets in a water soluble capsule or in a tablet compressed from the pellets, wherein each pellet contains (a) a...
6432447 Organic compounds  
An oral dosage form comprising fluvastatin and HPMC, which oral dosage form is color-stable upon prolonged periods of storage.
6432446 Non-arrhythmogenic metabolite of oxybutynin  
A method of treating disorders involving the urethrogentical tract by administering to pateints in need therof therapeutically effective amounts of the desethyl metabolite of oxybutynin and/or the...
6428810 Pharmaceutical formulation comprising omeprazole  
An enteric coated oral pharmaceutical formulation comprising as active ingredient a compound selected from the group of omeprazole, an alkaline salt of omeprazole, one of the single enantiomers of...
6426091 Sustained-release theophylline tablet  
A theophylline sustained release tablet obtained by coating core granules composed mainly of theophylline with a layer of a coating film composed of a hydrophobic material and a plastic excipient...
6423340 Method for the treatment of inflammatory bowel diseases  
Described herein are methods comprising the oral administration of budesonide for the treatment of ulcerative colitis and Crohn's colitis in its active phase. The methods can also be applied as...
6419959 Galenic composition containing opioid antagonists  
A pharmaceutical composition for oral administration contains naloxone-, N-methylnaloxone- and/or N-methylnaltrexone-containing particles which release the active substance depending on the...
6416786 Sustained release tablet containing hydrocolloid and cellulose ether  
The present invention is directed to a solid sustained release pharmaceutical tablet for administering to a host, comprising a therapeutically effective amount of a pharmaceutically active...
6413941 Polymer composition for delivering a nucleic acid or derivative thereof  
A composition for delivering a biologically active polyanionic molecule comprising a linear polymer with a backbone comprising amido and tertiary amino groups arranged regularly on the backbone...
6410517 Targeted gene delivery system  
A target-specific gene delivery system is made of enzymatically degradable gelatin and nucleic acids (DNA or RNA) microparticles with a linking moiety or a targeting ligand attached to the...
6410052 Tea catechins in sustained release formulations as cancer specific proliferation inhibitors  
The invention described herein encompasses a methods and compositions of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, a group...
6406716 Anticonvulsant containing composition for treating neuropathic pain  
The effectiveness of an anticonvulsant such as gabapentin for alleviating neuropathic pain is potentiated by a nontoxic antagonist for the N-methyl-D-aspartate receptor or nontoxic substance that...
6399100 Controlled release pharmaceutical compositions containing tiagabine  
Controlled release oral pharmaceutical preparations are provided which comprise a therapeutically effective amount of tiagabine or a pharmaceutically acceptable salt thereof dispersed in a rate...
6399096 Pharmaceutical formulation  
A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that...
6391341 Gastroresistant multi-unitary pharmaceutical preparations containing piroxicam  
The present invention relates to multi-unitary pharmaceutical preparations containing piroxicam for oral administration. Such pharmaceutical preparations are stable pellet pharmaceutical...
6387403 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing  
Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine...
6379700 Process for manufacturing tablets for the sustained release of active principle(s)  
The invention concerns a method for making tablets with active principle sustained-release which consists in: preparing a fluid oil-in-water emulsion; spraying the resulting emulsion on a powder...
6372252 Guaifenesin sustained release formulation and tablets  
The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a...
6372255 Tablet for instant and prolonged release of one or more active substances  
A multi-layer tablet for the instant and prolonged release of active substances comprises at least two layers where the first outer layer comprises a mixture of excipients and an active substance,...
6368625 Orally disintegrable tablet forming a viscous slurry  
A dosage form which rapidly disintegrates in the mouth and forms a viscous slurry of either microcapsules or a powder is described. The rapidly disintegrating dosage form is meant for direct oral...
6368638 Process of making an aqueous calcium carbonate suspension  
The present invention relates to a high dosage calcium carbonate aqueous antacid pharmaceutical suspension for oral use, and methods of preparation.
6365183 Method of fabricating a banded prolonged release active agent dosage form  
The present invention is directed to an active agent dosage form and methods of its fabrication which is useful for the prolonged delivery of an active agent formulation to a fluid environment of...
6365173 Stereocomplex polymeric carriers for drug delivery  
A polymeric carrier for delivery of bioactive or bioreactive molecules is provided, including a stereocomplex of one or more biocompatible polymers and having incorporated on or within the complex...
6365185 Self-destructing, controlled release peroral drug delivery system  
The present invention relates to tablets which are time-controlled to release active agent at different rates in different regions of the digestive tract in order to maintain a substantially...
6365182 Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet  
The present invention relates to a potassium containing dosage form which is capable of rapidly disintegrating in a patient's mouth to form an easy to swallow slurry.
6358525 Sustained release polymer blend for pharmaceutical applications  
A pharmaceutical composition has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is hydroxypropylcellulose (HPC)...
6355272 Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharamaceutical compositions  
A complex between carrageenan and a water soluble drug characterized in powder form having an average particle size comprised between 10 and 100 μm, and the basic water drug is contained in the...
6350471 Tablet comprising a delayed release coating  
The invention provides a delayed release tablet, comprising: (i) a core comprising an active ingredient selected from the group consisting of oxybutynin hydrochloride, propranolol hydrochloride,...
6348216 Ibuprofen and narcotic analgesic compositions  
Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising...
6346270 Phenytoin therapy  
A therapeutic composition, a dosage form and a method are disclosed for administering phenytoin indicated for the management of epilepsy.